Pharmaceutical Sciences Department, Feik School of Pharmacy, University of the Incarnate Word, San Antonio, TX 78209, USA.
Int J Mol Sci. 2023 Oct 18;24(20):15295. doi: 10.3390/ijms242015295.
In search of novel multi-mechanistic approaches for treating Alzheimer's disease (AD), we have embarked on synthesizing single small molecules for probing contributory roles of the following combined disease targets: sigma-1 (σ-1), class IIb histone deacetylase-6 (HDAC-6), and oxidative stress (OS). Herein, we report the synthesis and partial evaluation of 20 amides (i.e., phenylacetic and Trolox or 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid derivatives). Target compounds were conveniently synthesized via amidation by either directly reacting acyl chlorides with amines or condensing acids with amines in the presence of coupling agents 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b] pyridinium 3-oxide hexafluorophosphate (HATU) or 1,1'-carbonyldiimidazole (CDI). Overall, this project afforded compound as a promising lead with affinity (Ki = 2.1 μM), (IC = 17 nM), and (1.92 Trolox antioxidant equivalents or TEs) activities for optimization in ensuing structure-activity relationship (SAR) studies.
为了寻找治疗阿尔茨海默病(AD)的新型多机制方法,我们开始合成单一的小分子,以探究以下联合疾病靶点的促成作用:sigma-1(σ-1)、IIb 类组蛋白去乙酰化酶-6(HDAC-6)和氧化应激(OS)。在此,我们报告了 20 种酰胺(即苯乙酸和 Trolox 或 6-羟基-2,5,7,8-四甲基色烷-2-羧酸衍生物)的合成和部分评估。目标化合物通过酰氯与胺的直接反应或在偶联剂 1-[双(二甲氨基)亚甲基]-1H-1,2,3-三唑并[4,5-b]吡啶鎓 3-氧化物六氟磷酸盐(HATU)或 1,1'-碳酰二咪唑(CDI)的存在下与胺缩合方便地合成。总的来说,该项目提供了一种有前途的先导化合物,其对 σ-1 的亲和力(Ki = 2.1 μM)、对 HDAC-6 的抑制活性(IC = 17 nM)和对 OS 的 1.92 Trolox 抗氧化当量(TE)活性,为随后的构效关系(SAR)研究提供了优化的基础。